Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elranatamab + carfilzomib + dexamethasone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Subcutaneous (elranatamab), Intravenous (carfilzomib, Dexamethasone), Oral (dexamethasone)
01
Overview
This combination is an investigational regimen for relapsed or refractory multiple myeloma, currently in early phase clinical trials. **Elranatamab** is a bispecific monoclonal antibody targeting **B-cell maturation antigen (BCMA)** on myeloma cells and **CD3** on T cells, designed to redirect T cells to recognize and kill myeloma cells. **Carfilzomib** is a proteasome inhibitor, which leads to the accumulation of unwanted proteins in cancer cells, promoting apoptosis. **Dexamethasone** is a synthetic glucocorticoid corticosteroid used to reduce inflammation and enhance anti-myeloma effects. The combination is designed to attack myeloma cells through immune-mediated killing (via elranatamab), direct cytotoxicity (via carfilzomib), and modulation of the microenvironment and immune system (via dexamethasone)[1][4][8].
- Brand names
- Kyprolis (carfilzomib)
- Other names
- ELRA + CFZ + DEXElranatamab plus carfilzomib and dexamethasone
02
Targets
GR (Glucocorticoid receptor)BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on elranatamab + carfilzomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elranatamab + carfilzomib + dexamethasone.